Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATEC Alphatec	$10.99 -5.1%	$11.87	$4.88 ▼ $13.14	$1.61B	1.05	2.08 million shs	1.60 million shs
CSII Cardiovascular Systems	$20.00	$19.98	$12.26 ▼ $20.57	$843.96M	0.74	765,906 shs	4,300 shs
GNMK GenMark Diagnostics	$24.04	$24.02	$8.42 ▼ $24.25	$1.76B	3.02	2.70 million shs	N/A
LMNX Luminex	$36.99	$36.90	$20.61 ▼ $41.69	$1.75B	0.56	873,093 shs	N/A
LUNG Pulmonx	$2.90 +9.4%	$3.05	$2.50 ▼ $9.37	$116.75M	0.45	312,552 shs	1.79 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATEC Alphatec	0.00%	+0.05%	-3.34%	+12.72%	+2.04%
CSII Cardiovascular Systems	0.00%	0.00%	0.00%	0.00%	0.00%
GNMK GenMark Diagnostics	0.00%	0.00%	0.00%	0.00%	0.00%
LMNX Luminex	0.00%	0.00%	0.00%	0.00%	0.00%
LUNG Pulmonx	0.00%	+4.50%	-7.64%	-44.76%	-54.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATEC Alphatec	4.3615 of 5 stars	3.4	1.0	0.0	3.3	3.8	4.2	0.6
CSII Cardiovascular Systems	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNMK GenMark Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMNX Luminex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	3.4487 of 5 stars	3.3	5.0	0.0	0.0	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATEC Alphatec	2.89	Moderate Buy	$17.89	62.77% Upside
CSII Cardiovascular Systems	0.00	N/A	N/A	N/A
GNMK GenMark Diagnostics	0.00	N/A	N/A	N/A
LMNX Luminex	0.00	N/A	N/A	N/A
LUNG Pulmonx	2.63	Moderate Buy	$11.53	297.41% Upside

Current Analyst Ratings Breakdown

Latest ATEC, LUNG, CSII, LMNX, and GNMK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ATEC Alphatec	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$18.00
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/2/2025	ATEC Alphatec	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$13.00 ➝ $15.00
5/2/2025	ATEC Alphatec	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/14/2025	ATEC Alphatec	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATEC Alphatec	$611.56M	2.63	N/A	N/A	($0.10) per share	-109.90
CSII Cardiovascular Systems	$239.84M	3.52	N/A	N/A	$6.12 per share	3.27
GNMK GenMark Diagnostics	$88.02M	19.96	N/A	N/A	$0.21 per share	114.48
LMNX Luminex	$417.40M	4.19	$1.12 per share	32.98	$11.13 per share	3.32
LUNG Pulmonx	$83.79M	1.39	N/A	N/A	$2.17 per share	1.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATEC Alphatec	-$162.12M	-$1.15	N/A	N/A	N/A	-25.77%	-1,657.19%	-21.53%	7/30/2025 (Estimated)
CSII Cardiovascular Systems	-$36.93M	-$0.97	N/A	N/A	N/A	-15.79%	-15.39%	-11.93%	N/A
GNMK GenMark Diagnostics	-$47.35M	-$0.82	N/A	N/A	N/A	-16.95%	-39.36%	-13.02%	N/A
LMNX Luminex	$15.17M	$0.32	72.53	30.83	N/A	5.39%	4.66%	2.91%	N/A
LUNG Pulmonx	-$56.39M	-$1.44	N/A	N/A	N/A	-65.27%	-63.69%	-34.94%	7/30/2025 (Estimated)

Latest ATEC, LUNG, CSII, LMNX, and GNMK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	ATEC Alphatec	-$0.06	N/A	N/A	N/A	$178.85 million	N/A
7/30/2025	Q2 2025	LUNG Pulmonx	-$0.40	N/A	N/A	N/A	$23.46 million	N/A
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million
5/1/2025	Q1 2025	ATEC Alphatec	-$0.12	-$0.35	-$0.23	-$0.35	$167.57 million	$169.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATEC Alphatec	N/A	N/A	N/A	N/A	N/A
CSII Cardiovascular Systems	N/A	N/A	N/A	N/A	N/A
GNMK GenMark Diagnostics	N/A	N/A	N/A	N/A	N/A
LMNX Luminex	$0.40	1.08%	N/A	125.00%	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATEC Alphatec	N/A	2.75	1.67
CSII Cardiovascular Systems	0.08	6.04	4.92
GNMK GenMark Diagnostics	0.75	4.33	3.84
LMNX Luminex	0.52	8.37	6.08
LUNG Pulmonx	0.38	4.97	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATEC Alphatec	66.35%
CSII Cardiovascular Systems	86.61%
GNMK GenMark Diagnostics	96.94%
LMNX Luminex	87.76%
LUNG Pulmonx	91.04%

Insider Ownership

Company	Insider Ownership
ATEC Alphatec	20.90%
CSII Cardiovascular Systems	3.80%
GNMK GenMark Diagnostics	3.25%
LMNX Luminex	6.60%
LUNG Pulmonx	6.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATEC Alphatec	700	146.17 million	115.62 million	Optionable
CSII Cardiovascular Systems	780	42.20 million	40.59 million	Optionable
GNMK GenMark Diagnostics	618	73.09 million	N/A	Optionable
LMNX Luminex	1,325	47.31 million	N/A	Optionable
LUNG Pulmonx	250	40.26 million	37.52 million	Optionable

ATEC, LUNG, CSII, LMNX, and GNMK Headlines

Recent News About These Companies

Pulmonx Corporation (NASDAQ:LUNG) Receives $11.53 Average Target Price from Analysts

July 9, 2025 | americanbankingnews.com

Pulmonx Corporation (NASDAQ:LUNG) Receives Average Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | americanbankingnews.com

Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 6, 2025 | marketbeat.com

Richard Ferrari Sells 8,000 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

June 14, 2025 | insidertrades.com

Pulmonx Co. (NASDAQ:LUNG) Director Richard Ferrari Sells 8,000 Shares

June 13, 2025 | marketbeat.com

Pulmonx Corporation (LUNG) Stock Forecasts

June 8, 2025 | ca.finance.yahoo.com

Pulmonx Co. (NASDAQ:LUNG) Director Buys $71,362.26 in Stock

June 6, 2025 | insidertrades.com

Pulmonx Co. (NASDAQ:LUNG) Insider Sells $21,744.11 in Stock

June 5, 2025 | insidertrades.com

Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025 | globenewswire.com

Why Pulmonx Corporation’s (LUNG) Stock Is Down 5.82%

May 10, 2025 | aaii.comA

It’s Time to Recognize COPD as a Women’s Health Issue

May 8, 2025 | medscape.comM

Pulmonx Corporation (NASDAQ:LUNG) Q1 2025 Earnings Call Transcript

May 6, 2025 | msn.com

Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference

May 1, 2025 | globenewswire.com

Q1 2025 Pulmonx Corp Earnings Call

May 1, 2025 | finance.yahoo.com

Pulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ...

May 1, 2025 | uk.finance.yahoo.com

Pulmonx projects 20% long-term growth amid expanded initiatives and $12B market opportunity

April 30, 2025 | msn.com

Pulmonx Corporation (LUNG) Q1 2025 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

April 30, 2025 | zacks.com

Pulmonx Reports First Quarter 2025 Financial Results

April 30, 2025 | globenewswire.com

Pulmonx's Earnings Outlook

April 29, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Southwest Airlines: Short Interest Plunges—Should You Buy?
By Gabriel Osorio-Mazilli | June 17, 2025
View Southwest Airlines: Short Interest Plunges—Should You Buy?

ATEC, LUNG, CSII, LMNX, and GNMK Company Descriptions

Alphatec NASDAQ:ATEC

$10.99 -0.59 (-5.09%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.63 +0.64 (+5.81%)

As of 07/11/2025 07:56 PM Eastern

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

GenMark Diagnostics NASDAQ:GNMK

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.

Luminex NASDAQ:LMNX

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Pulmonx NASDAQ:LUNG

$2.90 +0.25 (+9.43%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.94 +0.04 (+1.38%)

As of 07/11/2025 07:57 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time